Management issues in dyspepsia: Current consensus and controversies

Scandinavian Journal of Gastroenterology

Volumn 39, Issue 10, 2004, Pages 913-918

  Talley, Nicholas J ^a   Vakil, N ^b   Delaney, B ^b   Marshall, B ^b   Bytzer, P ^b   Engstrand, L ^b   De Boer, W ^b   Jones, R ^b   Malfertheiner, P ^b   Agreus L ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DYSPEPSIA; ENDOSCOPY; ERADICATION THERAPY; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; LOW DRUG DOSE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW;

BREATH TESTS; CONSENSUS; DRUG THERAPY, COMBINATION; DYSPEPSIA; ENDOSCOPY, DIGESTIVE SYSTEM; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 6344294498     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520410003452     Document Type: Review

References (58)

1. Talley NJ, Silverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtmann G. AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998 114:582-95.
2. Talley NJ, Axon A, Bytzer P, Holtmann G, Lam SK, Van Zanten S. Management of uninvestigated and functional dyspepsia: a Working Party report for the World Congresses of Gastroenterology 1998. Aliment Pharmacol Ther 1999;13:1135-48.
3. Talley NJ, Lam SK, Goh KL, Fock KM. Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific Working Party on functional dyspepsia. J Gastroenterol Hepatol 1998;13:335-53.
4. Delaney BC, Wilson S, Roalfe A, Roberts L, Wearn A, Redman V, et al. A randomised controlled trial of Helicobacter pylori test and endoscopy for dyspepsia in primary care. Br Med J 2001;322:898-901.
5. Logan R, Delaney B. ABC of the upper gastrointestinal tract: implications of dyspepsia for the NHS. Br Med J 2001;323:675-7.
6. The Swedish Council on Technology Assessment in Health Care (SBU). Dyspepsia: methods of diagnosis and treatment. Summary and conclusions. Stockholm, Sweden. 2000.
7. Sjövall H. Dyspepsi-tarmbes vär (Dyspepsia - bowel complaint). http://www.sahlgrenska.se/vard/info/medinfo/dyspepsi/index.html Gothenburg, Sweden. 2001.
8. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. The European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
9. Rubin G, Meineche-Schmidt V, Roberts A, de Wit N. The use of consensus to develop guidelines for the management of Helicobacter pylori infection in primary care. European Society for Primary Care Gastroenterology. Fam Pract 2000;17 Suppl 2:S21-6.
10. Delaney BC, Moayyedi P, Forman D. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2003;(2):CD001961.
11. Talley NJ. Dyspepsia. Gastroenterology 2003;125:1219-26.
12. Thomson AB, Barkun AN, Armstrong D, Chiba N, White RJ, Daniels S, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003;17:1481-91.
13. Veldhuyzen van Zanten SJ, Flook N, Chiba N, Armstrong D, Barkun A, Bradette M, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ 2000;162 Suppl 12:S3-23.
14. Anonymous. An evidence-based appraisal of reflux disease management:the Genval Workshop Report. Gut 1999;44 Suppl 2:S1-16.
15. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999;45 Suppl:II37-42.
16. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson W, et al. U.S. householder survey of functional GI disorders: Prevalence, sociodemography and health impact. Dig Dis Sci 1993;38:1569-80.
17. Arents NL, Thijs JC, Kleibeuker JH. A rational approach to uninvestigated dyspepsia in primary care: review of the literature. Postgrad Med J 2002;78:707-16.
18. Talley NJ. Dyspepsia management in the millennium: the death of test and treat? Gastroenterology 2002;122:1521-5.
19. McColl KE, el-Nujumi A, Murray L, el-Omar E, Gillen D, Dickson A, et al. The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients. Gut 1997;40:302-6.
20. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003;(1):CD002096.
21. Sharma P, Vakil N. Helicobacter pylori and reflux disease. Aliment Pharmacol Ther 2003;17:297-305.
22. Uemura N, Okamoto S, Yamamoto S, Matsamura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
23. Huang J-Q, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a metta-analysis. Lancet 2002;359:14-22.
24. Pounder RE. Helicobacter pylori and NSAIDS: the end of the debate? Lancet 2002;359:34.
25. Laine L. The effect of Helicobacter pylori infection on non-steroidal anti-inflammatory drug-induced upper gastrointestinal tract injury. Aliment Pharmacol Ther 2002;16 Suppl 1:34-9.
26. Lai KC, Lau CS, Ip WY, Wong BC, Hui WM, Hu WH, et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003;17:799-805.
27. Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359:9-13.
28. Bannawarth B, Dorval E, Caekaert A, Barthelemy P. Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal anti-inflammatory drugs combined with omeprazole. J Rheumatol 2002;29:1975-80.
29. Okan A, Tankurt E, Aslan BU, Akpinar H, Sirnsek I, Gonen O. Relationship between non-steroidal anti-inflammatory drug use and Helicobacter pylori infection in bleeding or uncomplicated peptic ulcers: a case-control study. J Gastroenterol Hepatol 2003;18:18-25.
30. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002;16:779-86.
31. Allison JE, Hurley LB, Hiatt RA, Levin TR, Ackerson LM, Lieu TA. A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease. Arch Intern Med 2003;163:1165-71.
32. Ladabaum U, Fendrick AM, Glidden D, Scheiman JM. Helicobacter pylori test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United States. Am J Gastroenterol 2002;97:3007-14.
33. Sung JJ, Lao WC, Lai MS, Li TH, Chan FK, Wu JC, et al. Incidence of gastroesophageal malignancy in patients with dyspepsia in Hong Kong: implications for screening strategies. Gastrointest Endosc 2001;54:454-8.
34. Gatta L, Ricci C, Tampieri A, Vaira D. Non-invasive techniques for the diagnosis of Helicobacter pylori infection. Clin Microbiol Infect 2003;9-:489-96.
35. Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology. The essentials. 3rd ed. Baltimore, Williams & Wilkins; 1996. p. 69.
36. McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, Parkinson AJ, Morris JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003;139:463-9.
37. Malfertheiner P, Kirchner T, Kist M, Leodolter A, Peitz U, Strobel S, et al. BYK Advanced Gastric Ulcer Study Group. Helicobacter pylori eradication and gastric ulcer healing: comparison of three pantoprazole-based triple therapies. Aliment Pharmacol Ther 2003;17:1125-35.
38. Enroth H, Bjorkholm B, Engstrand L. Occurrence of resistance mutation and clonal expansion in Helicobacter pylori multiple-strain infection: a potential risk in clarithromycin-based therapy. Clin Infect Dis 1999;28:1305-7.
39. Sjolund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med 2003;139:483-7.
40. Blustein PK, Beck PL, Meddings JB, Van Rosendaal GM, Bailey RJ, Lalor E, et al. The utility of endoscopy in the management of patients with gastroesophageal reflux symptoms. Am J Gastroenterol 1998;93:2508-12.
41. Ford A, Delaney B, Moayyedi P. A systematic review of Helicobacter pylori eradication therapy in duodenal and gastric ulcer healing and maintenance. Gastroenterology 2003;124 Suppl 1:A359.
42. 2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. (Cochrane Review) In: The Cochrane Library, Issue 2, 2003 Oxford, Update Software.
43. 2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. Aliment Pharmacol Ther 2003;17:1215-27.
44. Manes G, Menchise A, De Nucci C, Balzano A. Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. Br Med J 2003;326:1118.
45. Stevens R, Baxter G. Benefit of Helicobacter pylori eradication in the treatment of ulcer-like dyspepsia in primary care. Gut 2001;49 Suppl II:A83.
46. Farkilla MA, Sarna S, Valtonen V, Sipponen P. Test & treat strategy for management of uninvestigated dyspepsia in primary health care. Gastroenterology 2000;118:A438.
47. Meineche-Schmidt V, Jorgensen T. 'Alarm symptoms' in patients with dyspepsia: a three-year prospective study from general practice. Scand J Gastroenterol 2002;37:999-1007.
48. Christie J, Shepherd NA, Codling BW, et al. Gastric cancer below the age of 55: implications for screening patients with uncomplicated dyspepsia. Gut 1997;41:513-7.
49. Gillen D, McColl KE. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol 1999;94:2329-30.
50. Canga C, 3rd, Vakil N. Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy. Am J Gastroenterol 2002;97:600-3.
51. Breslin NP, Thomson AB, Bailey RJ, et al. Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. Gut 2000;46:93-7.
52. Numans ME, van der Graaf Y, de Wit NJ, de Melker RA. How useful is selection based on alarm symptoms in requesting gastroscopy? An evaluation of diagnostic determinants for gastro-oesophageal malignancy. Scand J Gastroenterol 2001;36:437-43.
53. Nandurkar S, Talley NJ. Barrett's esophagus: the long and the short of it. Am J Gastroenterol 1999;94:30-40.
54. Spechler SJ. Managing Barrett's oesophagus. Br Med J 2003;326:892-4.
55. Delaney BC, Moayyedi P, Deeks J, Innes M, Soo S, Barton PM, et al. The management of dyspepsia: a systematic review. Health Technol Assess 2000;4:1-187.
56. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-9.
57. Moayyedi P, Wason C, Peacock R, Walan A, Bardhan K, Axon AT, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000;5:206-14.
58. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long-term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004;53:12-20.